Pyxis Oncology, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Pyxis Oncology announced positive preliminary Phase 1 data for its lead oncology candidate MICVO in HNSCC, both as monotherapy and in combination with KEYTRUDA, but reported significant losses and substantial doubt about its ability to continue as a going concern.
NASDAQ
Pyxis Oncology focuses on advancing its lead candidate, micvotabart pelidotin, for head and neck cancer treatment following encouraging Phase 1 trial results, while reporting a net loss of $77.3 million for 2024.
NASDAQ
10-K: Pyxis Oncology Provides Update on Clinical Programs and Corporate Strategy in Annual 10-K Filing
Pyxis Oncology's annual 10-K filing details the company's clinical progress, financial status, and strategic direction, highlighting its focus on novel cancer therapeutics.